GLP-1 Agonists and Health Coaching

Dr. Mark Pettus, Senior Medical Advisor at Preventia, discusses the alarming rise in obesity and cardiometabolic disease in the U.S., highlighting that nearly 75% of adults are now affected. He examines the role of GLP-1 agonists, originally developed to manage type 2 diabetes, in promoting weight loss and improving overall cardiometabolic health. While these medications have shown promising results, Dr. Pettus emphasizes that sustainable lifestyle changes are crucial for long-term success. Health coaching, when combined with GLP-1 agonists, offers a holistic approach to achieving lasting improvements in metabolic health.